About 95-98% of new anti-cancer drugs fail phase III clinical trials. Most drugs are made to target “bulk” cancer cells, but not the root cause: the cancer stem cell.  New therapies that specifically target and eradicate these cancer stem cells are needed to prevent tumors from growing and spreading, and we may then be able to turn cancer into a manageable chronic disease. (INDEPENDENT)